SMTI NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Sanara Medtech Inc · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 33.86 USD
32.5% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 57.3% above the Trend Line and sits at 89.5% of its 52-week range. The latest completed week returned 32.5%, after a 36.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 55/100. Near-term considerations: earnings are due in 11d.

Setup score 64 out of 100
Latest Close 33.86 USD 31 Jul 2026
1W Return 32.5% latest completed week
4W Return 36.3% short-term follow-through
12W Return 84.0% quarterly tape
Trend Breadth 15.4% 8 of 52 weeks active
Volume Ratio 7.2x vs 13-week average
What is working
  • The trend backdrop is active with a 4-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 36.85% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 32.5% Latest completed week; four-week move 36.3%. Indicator stack 22/79 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 36.85% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 55/100 55 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 57.3% above the Trend Line and sits at 89.5% of its 52-week range. The latest completed week returned 32.5%, after a 36.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 7.2x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.4912-week average 0.20

12-week confirmation

Trend active4/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.49Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 36.3% over four weeks, 84.0% over 12 weeks, and 40.1% over one year. The current trend has remained active for 4 consecutive weeks.

Performance by holding period

1W32.5%
4W36.3%
12W84.0%
26W53.9%
52W40.1%
Active trend streak4 weeks
Active weeks in one year8
Trend breadth15.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.49Latest activity-pressure read.
Pressure change28.6%Four-week change in activity pressure.
Leadership27.25Latest relative-leadership reading.
RS change340.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 88% Model confidence 84%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength11/100Blend of value, momentum, and quality. Underlying universe rank 90; rank 1 is best.
Value8/100Relative valuation strength. Underlying universe rank 93; rank 1 is best.
Quality71/100Profitability and accounting quality. Underlying universe rank 30; rank 1 is best.
Momentum25/100Medium-term price momentum. Underlying universe rank 76; rank 1 is best.
Growth77/100Revenue and earnings growth. Underlying universe rank 24; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
2.2x
Market value relative to trailing revenue.
EV / EBITDA
32.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
91.2%
Gross profit retained from each unit of revenue.
Operating margin
5.0%
Operating profit retained from revenue.
Free-cash-flow margin
8.6%
Free cash flow generated from revenue.
Return on invested capital
9.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
17.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
535.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
4.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity8 / 2

8 acquisitions and 2 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment55/100

Weighted news tone is neutral across 55 relevant articles.

18 positive · 33 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-5.8%Distance below the 52-week high.
13-week volatility10.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+32.5%Week of 31 Jul.
Worst week-8.0%Week of 6 Feb.
Latest week+32.5%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains4
Flat weeks0
Modest losses3
Sharp losses10
Recent vol10.2%13-week weekly-return volatility.
Base vol9.5%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew8.7% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape56/100

Trend, activity pressure, participation, and risk combine to a 56/100 tape read.

 Indicator analysis48/100

Latest 12-week confirmation: trend 4/12, activity pressure 12/12, relative leadership 1/12.

Activity pressure 0.49; No reversal markers Next-Week ExpectancyNegative 36.85%

Next-week expectancy is negative with a 36.85% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors28/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 60; Small Cap Core rank 95 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment55/100

Weighted news tone is neutral across 55 relevant articles.

Sanara MedTech Inc. (SMTI) filer’s amended 13G shows exit from share ownership Insiders8 / 2

8 acquisitions and 2 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202633.86 USD32.5%21.53 USD30.00 USD1.4927.254.3MOn
24 Jul 202625.56 USD2.2%21.17 USD30.06 USD1.37-3.15431.3KOn
17 Jul 202625.00 USD5.0%21.12 USD30.16 USD1.32-7.15310.2KOn
10 Jul 202623.82 USD-4.1%21.10 USD30.27 USD1.25-15.68305.6KOn
3 Jul 202624.84 USD4.0%21.17 USD30.37 USD1.16-11.34161.8KOff
26 Jun 202623.88 USD8.4%21.06 USD30.47 USD1.11-14.81380.2KOff
19 Jun 202622.02 USD5.8%20.96 USD30.57 USD1.01-25.64380.9KOff
12 Jun 202620.81 USD-7.3%20.88 USD30.69 USD1.03-28.61326.9KOff
5 Jun 202622.44 USD-1.5%20.90 USD30.82 USD1.11-22.20202.9KOff
29 May 202622.79 USD-1.6%21.08 USD30.93 USD0.89-25.39112.4KOff
22 May 202623.17 USD10.0%21.30 USD31.02 USD0.76-22.85199.8KOff
15 May 202621.06 USD14.5%21.56 USD31.10 USD0.48-29.92438.3KOff
8 May 202618.40 USD-6.7%21.80 USD31.20 USD0.24-39.81179.7KOff
1 May 202619.73 USD2.7%22.18 USD31.35 USD-0.19-33.13139.7KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.